Example: Heart Attack
Clinical Trials on Glabellar Crease
Total 10000 results
-
NCT06259162RecruitingTriple Negative Breast Cancer | Immune Checkpoint Inhibitor
-
NCT05831553RecruitingMetastatic Triple-negative Breast Cancer
-
NCT05491083RecruitingTriple Negative Breast Cancer | Advanced Solid Tumor
-
NCT05461690Not yet recruitingTriple Negative Breast Cancer | Homologous Recombination Deficiency
-
NCT05054777Not yet recruitingBreast Cancer Female | Patient Reported Outcome | Breast-conserving Surgery | Oncological Safety
-
NCT07134556WithdrawnTriple Negative Breast Cancer | PDL-1 Positive
-
NCT05382299Active, not recruiting
-
NCT05090358Active, not recruitingBreast Cancer | Metastatic Breast Cancer | Breast Cancer Stage IV
-
NCT05382286Active, not recruiting
-
NCT06765707Enrolling by invitationEndocrine Therapy | Breast Cancer Early Stage Breast Cancer (Stage 1-3)
-
NCT03654547CompletedAdvanced Solid Tumors | Triple Negative Breast Cancer
-
-
NCT04929197Enrolling by invitationBreast Cancer | Breast Neoplasms | Left Sided Breast Cancer
-
NCT03651921CompletedBreast Neoplasm | Self-Management | Intervention | Cancer Survivorship | Early-Stage Breast Cancer
-
NCT01908101CompletedStage IV Breast Cancer | Recurrent Breast Carcinoma
-
NCT03811418WithdrawnAdvanced Breast Cancer | HER2-positive Breast Cancer
-
NCT01009983TerminatedBreast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer
-
NCT01266213UnknownMetastatic Breast Cancer | Estrogen Receptor Positive Tumor | Breast Cancer Nos Premenopausal
-
NCT00004888CompletedCombination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast CancerStage IV Breast Cancer | Recurrent Breast Cancer
-
NCT00077363CompletedStage IV Breast Cancer | Recurrent Breast Cancer
-
NCT00025584CompletedStage IV Breast Cancer | Recurrent Breast Cancer
-
NCT03691311Active, not recruitingStage I Breast Cancer | Breast Neoplasm Female | Stage II Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Neoplasm
-
-
NCT07158021RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma
-
NCT06057636WithdrawnBreast Cancer | Neoplasm Metastasis | Triple Negative Breast Neoplasms | Inflammatory Breast Neoplasms | Inflammatory Breast Cancer Stage IV
-
NCT04073823TerminatedBreast Cancer Related Lymphedema
-
NCT04418219WithdrawnAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast Carcinoma | Refractory Breast Carcinoma
-
NCT03544125CompletedAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma
-
NCT02129686CompletedStage I Breast Cancer | Stage II Breast Cancer | Early-Stage Breast Carcinoma | Stage III Breast Cancer | Chemotherapy-induced Peripheral Neuropathy (CIPN) | Taxane-induced Peripheral Neuropathy
-
NCT07317778Not yet recruitingBreast Cancer Early Stage Breast Cancer (Stage 1-3) | HR Positive/HER2 Low Breast Cancer
-
NCT02961790CompletedHot Flashes | Breast Carcinoma | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | No Evidence of Disease
-
NCT02926690RecruitingRelapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
-
NCT00699491CompletedCixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerRecurrent Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7
-
-
NCT06463626CompletedHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone-receptor-positive Breast Cancer
-
NCT04190056TerminatedAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8
-
NCT02078752TerminatedNeoplasms | Triple-Negative Breast Cancer
-
NCT06876714RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Early Stage Breast Carcinoma
-
NCT05595499RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8
-
NCT04329065RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8
-
NCT04443413Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8
-
NCT04443348Active, not recruitingTriple Negative Breast Cancer | Hormone Receptor Positive (HR+), HER2-negative Breast Cancer | Biopsy-proven, Positive Lymph Node(s)
-
NCT06193070CompletedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8
-
NCT03748030UnknownRadiation Toxicity | Left-Sided Breast Cancer
-
NCT07111832RecruitingPD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
-
NCT06843681Enrolling by invitation
-
NCT03803761WithdrawnAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma
-
NCT06927180RecruitingBreast Cancer Early Stage Breast Cancer (Stage 1-3)
-
NCT04664829CompletedMetastatic Triple-Negative Breast Carcinoma
-
NCT01948726CompletedBreast Cancer After Breast Conserving Surgery Indicating Postoperative Radiotherapy With Boost
-
NCT02789332CompletedBreast Cancer | Triple Negative Breast Neoplasms | HRpos Breast Neoplasms | BRCA 1 /2 and / or HRD
-
NCT02876107Active, not recruitingEdema | Erythema | Breast Carcinoma | Invasive Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Inflammatory Breast Carcinoma | Breast Lump
-
NCT05263362CompletedBreast Cancer | Breast Neoplasms | Breast Carcinoma | Breast Cancer Female | Breast Carcinoma in Situ | Breast Fibrosis